← GeneDx overview

GeneDx vs Danaher: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GeneDx Holdings Corp. (WGS)

Q3 2026
▲2▼2

GeneDx Faces Legal Woes, Reaffirms Outlook, Raises Capital

  • Securities Fraud Lawsuits Continue Multiple law firms filed securities fraud class actions over the Fabric Genomics acquisition, which was written down by $31.2 million and triggered a 49% stock collapse. The August 3 lead plaintiff deadline keeps legal uncertainty alive, weighing on shares.

    This is the main negative force, with ongoing lawsuits and a key deadline during the period.

  • Reaffirmed 2026 Revenue Outlook GeneDx reaffirmed its 2026 revenue outlook, easing fears of further downgrades after a 12% guidance cut. This signals management confidence in the business despite legal challenges.

    This positive news provided reassurance to investors and supported the stock.

  • Raised $5 Million from Blackstone Affiliate GeneDx raised about $5 million from a Blackstone affiliate at $61 per share, signaling confidence from a major investor. This capital infusion strengthens the balance sheet amid ongoing legal costs.

    This capital raise is a new positive development that shows institutional support.

  • Q2 Net Loss Leaves Profitability Unproven Q2 revenue was $114.44 million but net loss was $17.74 million, leaving profitability unproven. This financial performance raises concerns about the company's path to profitability.

    The Q2 earnings report is a key new data point that highlights ongoing financial challenges.

July 2026
▲2▼2

GeneDx Faces Legal Woes, Reaffirms Outlook, Raises Capital

  • Securities Fraud Lawsuits Continue Multiple law firms filed securities fraud class actions over the Fabric Genomics acquisition, which was written down by $31.2 million and triggered a 49% stock collapse. The August 3 lead plaintiff deadline keeps legal uncertainty alive, weighing on shares.

    This is the main negative force, with ongoing lawsuits and a key deadline during the period.

  • Reaffirmed 2026 Revenue Outlook GeneDx reaffirmed its 2026 revenue outlook, easing fears of further downgrades after a 12% guidance cut. This signals management confidence in the business despite legal challenges.

    This positive news provided reassurance to investors and supported the stock.

  • Raised $5 Million from Blackstone Affiliate GeneDx raised about $5 million from a Blackstone affiliate at $61 per share, signaling confidence from a major investor. This capital infusion strengthens the balance sheet amid ongoing legal costs.

    This capital raise is a new positive development that shows institutional support.

  • Q2 Net Loss Leaves Profitability Unproven Q2 revenue was $114.44 million but net loss was $17.74 million, leaving profitability unproven. This financial performance raises concerns about the company's path to profitability.

    The Q2 earnings report is a key new data point that highlights ongoing financial challenges.

Latest
▲2▼1

GeneDx hit by Fabric Genomics lawsuits, then reaffirms outlook and raises cash

  • Securities class actions pile up over Fabric Genomics Multiple law firms filed class actions claiming GeneDx misled investors about the Fabric Genomics acquisition, the durability of reimbursement rates and gross margins. Lawsuits can mean legal costs, management distraction and reputational damage, all of which weigh on the stock.

    The wave of lawsuits is the dominant new negative force this period.

  • GeneDx reaffirms 2026 outlook GeneDx stood by its full-year 2026 revenue guidance, signaling the May guidance cut is holding rather than worsening. For investors worried about another downgrade, a stable outlook removes a key fear and supports the share price.

    Reaffirmed guidance is the main new fundamental signal countering the legal overhang.

  • Blackstone affiliate injects fresh capital GeneDx raised about $5 million selling shares at $61 each to a Blackstone affiliate. The sum is small, but backing from a major investor signals confidence and adds cash as the company expands into pediatric and NICU markets.

    New outside capital and a marquee backer are a fresh positive for the stock.

  • Q2 shows revenue but still a net loss Second-quarter revenue was $114.44 million with a $17.74 million net loss. Sales are real, but the company still loses money, so the path to profit remains unproven and keeps pressure on the shares.

    The Q2 numbers are new and show both the growth story and its profitability risk.

▼1

GeneDx Legal Cloud Persists as August 3 Lead Plaintiff Deadline Nears

  • August 3 lead plaintiff deadline keeps lawsuit in focus Investors have until August 3, 2026 to ask to lead the securities fraud class action over the Fabric Genomics deal. The deadline keeps the allegations in the news and stretches out uncertainty, which tends to hold the stock down until the matter is resolved.

    This is the only new development this period — the deadline is approaching and multiple firms are reminding investors, which keeps the legal overhang active.

▼3

GeneDx Lawsuits Over Fabric Genomics Keep Piling Up

  • Law firms keep pressing the Fabric Genomics fraud case Multiple law firms are now investigating or reminding investors about the securities fraud class action tied to the Fabric Genomics deal. Each new firm joining keeps the legal cloud over GeneDx, and the threat of penalties and damaged management credibility weighs on the stock.

    Shows the legal pressure is broadening, not fading, which is the main new force on WGS.

  • August 3 deadline keeps the lawsuit in the spotlight Investors have until August 3, 2026 to ask to lead the case. That date keeps the allegations in the news and stretches out the uncertainty, which tends to hold the stock down until the matter is resolved.

    The approaching deadline is a concrete new event that keeps negative attention on the stock.

  • The $31.2 million write-off is the heart of the case The lawsuits center on the Fabric Genomics purchase, which GeneDx wrote down by $31.2 million — nearly all the cash it paid a year earlier. That failed deal, plus a 12% guidance cut, is what triggered the 49% stock collapse.

    Explains the underlying business failure that all the new legal stories are built on.

Q2 2026
▼3

GeneDx Hit by Securities Fraud Lawsuits Over Fabric Genomics

  • Securities fraud class action filed A securities fraud class action alleges GeneDx misled investors about the Fabric Genomics acquisition. The lawsuit creates legal uncertainty and potential financial penalties, weighing on WGS shares as investors worry about liability and management credibility.

    This is the main new event of the period and directly explains negative pressure on WGS.

  • Lead plaintiff deadline set for August 3 Investors have until August 3, 2026, to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the spotlight, reminding the market of the allegations and prolonging uncertainty that can hold the stock down.

    The deadline is a new concrete development that sustains negative attention on WGS.

  • CFO sells shares to cover taxes GeneDx's CFO sold $227,000 in stock on June 16 to cover tax obligations from vesting restricted shares. While not a discretionary sale, it can still unsettle investors by signaling insider selling, adding mild downward pressure.

    This is a new insider transaction that may affect investor sentiment.

June 2026
▼3

GeneDx Hit by Securities Fraud Lawsuits Over Fabric Genomics

  • Securities fraud class action filed A securities fraud class action alleges GeneDx misled investors about the Fabric Genomics acquisition. The lawsuit creates legal uncertainty and potential financial penalties, weighing on WGS shares as investors worry about liability and management credibility.

    This is the main new event of the period and directly explains negative pressure on WGS.

  • Lead plaintiff deadline set for August 3 Investors have until August 3, 2026, to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the spotlight, reminding the market of the allegations and prolonging uncertainty that can hold the stock down.

    The deadline is a new concrete development that sustains negative attention on WGS.

  • CFO sells shares to cover taxes GeneDx's CFO sold $227,000 in stock on June 16 to cover tax obligations from vesting restricted shares. While not a discretionary sale, it can still unsettle investors by signaling insider selling, adding mild downward pressure.

    This is a new insider transaction that may affect investor sentiment.

▼3

GeneDx Hit by Securities Fraud Lawsuits Over Fabric Genomics

  • Securities fraud class action filed A securities fraud class action alleges GeneDx misled investors about the Fabric Genomics acquisition. The lawsuit creates legal uncertainty and potential financial penalties, weighing on WGS shares as investors worry about liability and management credibility.

    This is the main new event of the period and directly explains negative pressure on WGS.

  • Lead plaintiff deadline set for August 3 Investors have until August 3, 2026, to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the spotlight, reminding the market of the allegations and prolonging uncertainty that can hold the stock down.

    The deadline is a new concrete development that sustains negative attention on WGS.

  • CFO sells shares to cover taxes GeneDx's CFO sold $227,000 in stock on June 16 to cover tax obligations from vesting restricted shares. While not a discretionary sale, it can still unsettle investors by signaling insider selling, adding mild downward pressure.

    This is a new insider transaction that may affect investor sentiment.

Danaher Corporation (DHR)

Q3 2026
▲2▼2

Danaher's mixed Q3: biotech growth offset by guidance cuts and Masimo deal concerns

  • Biotech growth and product clearances Danaher's biotech segment grew 7% with strong bioprocessing orders, and it won FDA clearance for Masimo's AI opioid-detection feature and a CE Mark for Beckman Coulter's Alzheimer's blood test, signaling innovation momentum.

    These positive developments show underlying demand and product progress that supported the stock.

  • Strategic acquisitions and AI lab launch Leica Biosystems closed its StatLab acquisition, and Danaher launched its first AI-powered autonomous antibody lab at Abcam, potentially making custom antibodies up to 8x faster, which could drive future efficiency and growth.

    These moves expand Danaher's capabilities and may enhance long-term competitiveness.

  • Guidance cuts and revenue shift Danaher twice cut core growth guidance due to weak respiratory testing and over $100 million in bioprocessing revenue shifting to 2027, while biotech consumables missed on shipment timing, raising doubts about the recovery pace.

    These cuts directly lowered expectations and pressured the stock.

  • Masimo acquisition concerns The $9.9 billion Masimo acquisition weighed on shares amid debt, integration, and Apple patent concerns, adding uncertainty and financial risk.

    The large deal introduced balance sheet and legal risks that investors worried about.

September 2026
▲3▼1

Danaher trims growth outlook, but AI lab and deal build new story

  • Danaher cuts core growth guidance as recovery lags peers Danaher lowered the top of its full-year core revenue growth outlook to 3%-4% from 3%-6%, blaming weaker respiratory testing and a $100 million order pushed into next year. Thermo Fisher and Medtronic raised guidance, so investors see Danaher's recovery as slower and less certain, which weighs on the stock.

    This is the main negative force this period and explains why the stock lagged peers.

  • Leica Biosystems closes StatLab acquisition Danaher's Leica Biosystems completed its purchase of StatLab Medical Products, adding pre-analytical consumables and equipment to its pathology business. It expands Danaher's diagnostics offerings and cross-selling opportunities, a modest positive that supports long-term revenue growth even if it doesn't change near-term numbers much.

    A concrete completed deal that adds to Danaher's diagnostics portfolio and future revenue.

  • First AI-powered autonomous lab for antibody research Danaher announced its first AI-powered autonomous lab at Abcam, combining AI, robotics and its operating companies' tools to make custom antibodies up to 8x faster. It signals a higher-value, automation-led growth story, and the stock rose about 2% premarket on the news, though real revenue is not expected until early 2027.

    This is the clearest new positive catalyst and shows Danaher's AI/automation strategy.

  • Barclays raises Danaher price target to $255 Barclays lifted its Danaher price target to $255 from $230 while keeping an Overweight rating, citing confidence in the company's outlook. Analyst upgrades can draw in buyers and support the share price, though they reflect opinion rather than a change in Danaher's actual business results.

    A fresh analyst move that can influence near-term investor demand for the stock.

Latest
▲3▼1

Danaher trims growth outlook, but AI lab and deal build new story

  • Danaher cuts core growth guidance as recovery lags peers Danaher lowered the top of its full-year core revenue growth outlook to 3%-4% from 3%-6%, blaming weaker respiratory testing and a $100 million order pushed into next year. Thermo Fisher and Medtronic raised guidance, so investors see Danaher's recovery as slower and less certain, which weighs on the stock.

    This is the main negative force this period and explains why the stock lagged peers.

  • Leica Biosystems closes StatLab acquisition Danaher's Leica Biosystems completed its purchase of StatLab Medical Products, adding pre-analytical consumables and equipment to its pathology business. It expands Danaher's diagnostics offerings and cross-selling opportunities, a modest positive that supports long-term revenue growth even if it doesn't change near-term numbers much.

    A concrete completed deal that adds to Danaher's diagnostics portfolio and future revenue.

  • First AI-powered autonomous lab for antibody research Danaher announced its first AI-powered autonomous lab at Abcam, combining AI, robotics and its operating companies' tools to make custom antibodies up to 8x faster. It signals a higher-value, automation-led growth story, and the stock rose about 2% premarket on the news, though real revenue is not expected until early 2027.

    This is the clearest new positive catalyst and shows Danaher's AI/automation strategy.

  • Barclays raises Danaher price target to $255 Barclays lifted its Danaher price target to $255 from $230 while keeping an Overweight rating, citing confidence in the company's outlook. Analyst upgrades can draw in buyers and support the share price, though they reflect opinion rather than a change in Danaher's actual business results.

    A fresh analyst move that can influence near-term investor demand for the stock.

July 2026
▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

  • Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.

    The acquisition is the biggest new event and main reason for the stock's decline.

  • Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.

    This guidance cut directly impacts investor expectations and the stock's valuation.

  • Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.

    The miss highlights execution risks and weighs on sentiment.

  • Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.

    These positives show underlying business strength and innovation, providing a counterweight to the negatives.

▲3▼1

Danaher cuts growth outlook, but core biotech and diagnostics still support

  • Full-year core revenue growth outlook cut to 4% from 6% Danaher lowered the top end of its 2026 core revenue growth forecast to 4% from 6%, citing weaker respiratory testing and over $100 million in bioprocessing revenue shifting to next year. This signals slower demand ahead, pushing the stock down as investors worry about future growth.

    This is the main new negative event that directly answers why DHR is moving right now.

  • Q2 earnings beat and raised EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45–$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.

    This is a new positive counterweight that helps explain the mixed picture and potential support for the stock.

  • Biotech orders grow mid-teens, but revenue timing shifts Danaher's bioprocessing orders grew mid-teens, indicating strong underlying demand, but weaker-than-expected biotechnology revenue and a shift of over $100 million into next year weighed on results. This creates a mixed picture: strong future demand but near-term revenue miss.

    This explains the nuance behind the revenue miss and why the stock reaction may be overdone.

  • Analysts see stock as undervalued after sell-off A Simply Wall St analysis suggests Danaher is 16% undervalued based on earnings and 2026 revenue guidance, with a fair value estimate of $228.61. BofA maintained a Buy rating but cut its price target to $230 from $270. This could attract value investors and support the stock.

    This provides a potential positive catalyst and shows analyst views on valuation after the decline.

▲2▼2

Danaher's Q2 Beat Marred by Weak Guidance and Biotech Shipment Shift

  • Weak Q3 revenue guidance triggers sell-off Danaher guided Q3 core revenue growth to just 2-3%, far below expectations, despite beating Q2 estimates. This signals slower demand ahead, pushing the stock down sharply as investors worry about future growth.

    This is the main new event that caused the stock to drop over 10% this period.

  • Biotech consumables sales miss due to shipment timing High-margin biotech consumables missed expectations because a few large chromatography resin shipments moved out of the year. This reduces near-term revenue and profit, and the market fears it could signal broader weakness.

    This explains the specific reason behind the guidance cut and the stock's decline.

  • Q2 earnings beat and raised full-year EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45-$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.

    This is a key positive from the quarter that contrasts with the negative reaction.

  • Analysts see sell-off as overreaction and buying opportunity The 12% weekly drop is viewed by some analysts as an overreaction to a timing issue, not a fundamental problem. If shipments shift to later quarters, revenue will still be recognized, making the decline a potential buying opportunity for long-term investors.

    This provides a counterweight to the negative news and suggests the stock may rebound.

▲3▼1

Danaher's Masimo Bet Faces Doubts as Core Biotech Shows Strength

  • Masimo acquisition drags on stock Danaher's $9.9 billion purchase of Masimo has pushed shares down 22% this year. Investors worry about added debt, integration challenges, and a patent fight with Apple. This weighs on the stock because it increases risk and uncertainty.

    Explains the main reason DHR is down this year and the key overhang on the stock.

  • Masimo unit gets FDA clearance for AI opioid detection Masimo received FDA clearance for an AI feature that detects opioid-induced breathing problems. This is a first-of-its-kind product that could boost sales and shows the acquisition is already producing innovative products, lifting investor sentiment.

    Shows a concrete positive from the Masimo deal that could drive future revenue and improve sentiment.

  • Biotech segment core revenues grow 7% Danaher's Biotechnology segment saw core revenues rise 7% in Q1 2026, with bioprocessing equipment orders up over 30%. This indicates strong demand for the company's core products, which supports revenue growth and profitability, pushing the stock up.

    Highlights the strong performance of Danaher's core business, a key driver of earnings and stock price.

  • Beckman Coulter wins CE Mark for Alzheimer's blood test Danaher's Beckman Coulter received CE Mark for its p-Tau217 blood assay, allowing sales in Europe. This regulatory win opens a new market for a potentially high-demand Alzheimer's test, adding a future revenue stream and boosting the stock.

    Represents a new product approval that expands Danaher's diagnostics offerings and could drive growth.